Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST-CARE trial)

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515333-14-00

Enrollment

444

Registered

2025-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for major surgery for oncologic indication

Brief summary

to test the efficacy of preoperative ketorolac followed by postoperative, dietary and pharmacologic glycemic/inflammatory control (through a combination of Mediterranean diet and low-dose aspirin) in reducing 90-day surgery-related morbidity (grade 3 or more according to the Clavain Dindo Classification) in high-risk patients (those with an RBT≥18) undergoing major surgical procedures

Interventions

DRUGTora-Dol 30 mg/ml soluzione iniettabile

DRUGAcido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti

DRUGSODIO CLORURO 0

DRUG9% BAXTER Soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
to test the efficacy of preoperative ketorolac followed by postoperative, dietary and pharmacologic glycemic/inflammatory control (through a combination of Mediterranean diet and low-dose aspirin) in reducing 90-day surgery-related morbidity (grade 3 or more according to the Clavain Dindo Classification) in high-risk patients (those with an RBT≥18) undergoing major surgical procedures	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026